Pierre and Marie Curie University-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2021

  1. Translational epigenetics in precision medicine of colorectal cancer

    Epigenetics in Precision Medicine (Elsevier), pp. 19-41

2019

  1. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine

    Kidney International, Vol. 96, Núm. 3, pp. 555-567

2017

  1. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 28, pp. iv22-iv40

2015

  1. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

    Clinical Cancer Research, Vol. 21, Núm. 24, pp. 5469-5479

2014

  1. Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer

    Annals of Oncology, Vol. 25, Núm. 1, pp. 107-116

2010

  1. Panitumumab with FOLFIRI versus FOLFIRI alone: results from a randomised phase III study of second-line treatment of patients with metastatic colorectal cancer (mCRC)

    ONKOLOGIE

2009

  1. Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)

    EJC SUPPLEMENTS

2005

  1. Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)expressing metastatic colorectal cancer (mCRC) in the first-line setting:: a phase II study

    EJC SUPPLEMENTS